| <H1>
Search Pakistan
</H1> |
| <H2> Saturday, October 29, 2016 </H2> |
| <H2> 1. name Of The Medicinal Product </H2> |
| <H2> </H2> |
| <H2> 2. Qualitative And Quantitative Composition </H2> |
| <H2> 3. Pharmaceutical Form </H2> |
| <H2> 4. Clinical Particulars </H2> |
| <H2> 5. Pharmacological Properties </H2> |
| <H2> 6. Pharmaceutical Particulars </H2> |
| <H2> 7. Marketing Authorisation Holder </H2> |
| <H2> 8. Marketing Authorisation Number(S) </H2> |
| <H2> 9. Date Of First Authorisation/Renewal Of The Authorisation </H2> |
| <H2> 10. Date Of Revision Of The Text </H2> |
| <H2> Friday, October 28, 2016 </H2> |
| <H2> 1. name Of The Medicinal Product </H2> |
| <H2> </H2> |
| <H2> 2. Qualitative And Quantitative Composition </H2> |
| <H2> 3. Pharmaceutical Form </H2> |
| <H2> 4. Clinical Particulars </H2> |
| <H2> Commonly used brand name(s) </H2> |
| <H2> Uses For Istodax </H2> |
| <H2> Before Using Istodax </H2> |
| <H2> Proper Use of Istodax </H2> |
| <H2> Precautions While Using Istodax </H2> |
| <H2> Istodax Side Effects </H2> |
| <H2> More Istodax resources </H2> |
| <H2> Compare Istodax with other medications </H2> |
| <H2> 1. name Of The Medicinal Product </H2> |
| <H2> </H2> |
| <H2> 2. Qualitative And Quantitative Composition </H2> |
| <H2> 3. Pharmaceutical Form </H2> |
| <H2> 4. Clinical Particulars </H2> |
| <H2> 5. Pharmacological Properties </H2> |
| <H2> 6. Pharmaceutical Particulars </H2> |
| <H2> 7. Marketing Authorisation Holder </H2> |
| <H2> 8. Marketing Authorisation Number(S) </H2> |
| <H2> 9. Date Of First Authorisation/Renewal Of The Authorisation </H2> |
| <H2> 10. Date Of Revision Of The Text </H2> |
| <H2> About Me </H2> |
| <H2> Blog Archive </H2> |
| <H3>
Aknemin 100
</H3> |
| <H3> 4.1 Therapeutic Indications </H3> |
| <H3> 4.2 Posology And Method Of Administration </H3> |
| <H3> 4.3 Contraindications </H3> |
| <H3> 4.4 Special Warnings And Precautions For Use </H3> |
| <H3> 4.5 Interaction With Other Medicinal Products And Other Forms Of Interaction </H3> |
| <H3> 4.6 Pregnancy And Lactation </H3> |
| <H3> 4.7 Effects On Ability To Drive And Use Machines </H3> |
| <H3> 4.8 Undesirable Effects </H3> |
| <H3> 4.9 Overdose </H3> |
| <H3> 5.1 Pharmacodynamic Properties </H3> |
| <H3> 5.2 Pharmacokinetic Properties </H3> |
| <H3> 5.3 Preclinical Safety Data </H3> |
| <H3> 6.1 List Of Excipients </H3> |
| <H3> 6.2 Incompatibilities </H3> |
| <H3> 6.3 Shelf Life </H3> |
| <H3> 6.4 Special Precautions For Storage </H3> |
| <H3> 6.5 Nature And contents Of Container </H3> |
| <H3> 6.6 Special Precautions For Disposal And Other Handling </H3> |
| <H3>
Naropin 2 mg / ml solution for infusion
</H3> |
| <H3> 4.1 Therapeutic Indications </H3> |
| <H3> 4.2 Posology And Method Of Administration </H3> |
| <H3> 4.3 Contraindications </H3> |
| <H3> 4.4 Special Warnings And Precautions For Use </H3> |
| <H3> 4.5 Interaction With Other Medicinal Products And Other Forms Of Interaction </H3> |
| <H3> 4.6 Pregnancy And Lactation </H3> |
| <H3> 4.7 Effects On Ability To Drive And Use Machines </H3> |
| <H3> 4.8 Undesirable Effects </H3> |
| <H3> 4.9 Overdose </H3> |
| <H3>
Istodax
</H3> |
| <H3> Allergies </H3> |
| <H3> Pediatric </H3> |
| <H3> Geriatric </H3> |
| <H3> Pregnancy </H3> |
| <H3> Breast Feeding </H3> |
| <H3> Interactions with Medicines </H3> |
| <H3> Interactions with Food/Tobacco/Alcohol </H3> |
| <H3> Other Medical Problems </H3> |
| <H3>
ACWY Vax Vaccine
</H3> |
| <H3> 4.1 Therapeutic Indications </H3> |
| <H3> 4.2 Posology And Method Of Administration </H3> |
| <H3> 4.3 Contraindications </H3> |
| <H3> 4.4 Special Warnings And Precautions For Use </H3> |
| <H3> 4.5 Interaction With Other Medicinal Products And Other Forms Of Interaction </H3> |
| <H3> 4.6 Pregnancy And Lactation </H3> |
| <H3> 4.7 Effects On Ability To Drive And Use Machines </H3> |
| <H3> 4.8 Undesirable Effects </H3> |
| <H3> 4.9 Overdose </H3> |
| <H3> 5.1 Pharmacodynamic Properties </H3> |
| <H3> 5.2 Pharmacokinetic Properties </H3> |
| <H3> 5.3 Preclinical Safety Data </H3> |
| <H3> 6.1 List Of Excipients </H3> |
| <H3> 6.2 Incompatibilities </H3> |
| <H3> 6.3 Shelf Life </H3> |
| <H3> 6.4 Special Precautions For Storage </H3> |
| <H3> 6.5 Nature And contents Of Container </H3> |
| <H3> 6.6 Special Precautions For Disposal And Other Handling </H3> |
Sociaal
Sociale data
De kosten maakte het gebruiken van deze semi-publieke manier van communiceren onhaalbaar.
Maar door de groei van sociale netwerken tussen 2004 en 2010 heeft het gebruik hiervan mogelijk gemaakt.